What can be done to help predict which patients might experience durable responses to targeted therapy, like Sarah's?
Factors that might predict the benefit over a long period of time for targeted therapy are currently under development. The research space, what we have available now really, are clinical factors such as ageyounger being more likely to respond and do better over time—low LDH, sites of disease being less than three and not liver metastases as well as not brain metastases obviously. Those are really the predictors that we have to try to identify patients right now.
CASE: Metastatic Melanoma
Sarah is a 50-year-old Caucasian postal worker who presented to her primary care physician with multiple, skin-colored nodules and palpable lymph nodes. .
The patient was started on the combination of dabrafenib and trametinib. She experienced a durable complete response and has remained on therapy for 36 months.
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Read More
EFS Benefit of Pembrolizumab Is Shown in Neoadjuvant, Adjuvant Setting
June 27th 2024Douglas B. Johnson, MD, MSCI, offers a comprehensive exploration of the nuances for using neoadjuvant therapy, addressing various treatment combinations, along with recommendations for first-line systemic therapy.
Read More